Correction to: Oncogene (2017) 36, 4778–4789; doi:10.1038/onc.2017.93; published online 17 April 2017
Following the publication of this article the authors noted that the description of Figure 4a and Supplementary Figure S2 needed to be corrected for appropriateness in the main text. The passage on page 2 of the PDF was consequently amended to read:
‘We then tested if rocaglamide treatment could inhibit KRAS-GTP in cells carrying mutated KRAS. Interestingly, treatment of both 482T1 (Supplementary Figure S2A) and NCI-H226 cells (wild type KRAS) with rocaglamide led to inhibition of RAS-GTP loading in these cells in a concentration-dependent manner (Figure 4a and Supplementary Figure S2B). We then checked…’
The authors apologise for any inconvenience this might have caused.
Additional information
The online version of the original article can be found at 10.1038/onc.2017.93
Rights and permissions
About this article
Cite this article
Yurugi, H., Marini, F., Weber, C. et al. Erratum: Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. Oncogene 36, 5914 (2017). https://doi.org/10.1038/onc.2017.307
Published:
Issue date:
DOI: https://doi.org/10.1038/onc.2017.307
